Drug intelligence / Profile preview

pomalidomide + rituximab + anti-PD-1 antibody

Development stage: Preclinical
Lead developer: Zhejiang Province Cancer Hospital
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination immunotherapy regimen consisting of pomalidomide (an immunomodulatory drug), rituximab (an anti-CD20 monoclonal antibody), and an anti-PD-1 antibody. This triple therapy aims to enhance anti-tumor immune responses through multiple mechanisms: pomalidomide's immunomodulatory effects, rituximab's targeting of CD20-expressing B cells, and anti-PD-1's prevention of T-cell exhaustion. The combination is being investigated for the treatment of relapsed/refractory lymphomas, particularly in patients who have received multiple prior lines of therapy.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on pomalidomide + rituximab + anti-PD-1 antibody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pomalidomide + rituximab + anti-PD-1 antibody.

Explore the full profile